Axumin Safety Profile
Not an actual patient.
From industry-sponsored trials1,2
| Preferred term | Frequency Number of patients (%) Total N=877 | Intensity Mild | Moderate | Severe | ||
|---|---|---|---|---|
| Mild | Moderate | Severe | ||
| Any event | 9 (1.0%) | 8 | 1 | |
| Injection site erythema | 2 (0.2%) | 2 | ||
| Injection site pain | 2 (0.2%) | 2 | ||
| Dysgeusia | 2 (0.2%) | 2 | ||
| Constipation | 1 (0.1%) | 1 | ||
| Headache | 1 (0.1%) | 1 | ||
| Parosmia | 1 (0.1%) | 1 | ||
No known interactions with androgen deprivation therapy (ADT)1
No contraindications1
Adverse reactions were reported in ≤1% of patients during clinical studies1
References: 1. Axumin. Package insert. Blue Earth Diagnostics Ltd; 2022. 2. Data on file. Blue Earth Diagnostics, Ltd. Oxford, UK.
INDICATION | IMPORTANT SAFETY INFORMATION
INDICATION
Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
IMPORTANT SAFETY INFORMATION
- Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
- Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
- Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
- Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.
To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see Axumin full Prescribing Information.